These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28830872)

  • 21. Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.S.-born, Jamaican, and Haitian black men: a pilot study.
    Chen AC; MacChia RJ; Conway F; Magai C; Desai M; Neugut AI
    Urology; 2004 Sep; 64(3):522-7. PubMed ID: 15351583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating steroid hormones and the risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley W; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):86-91. PubMed ID: 16434592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.
    Black A; Pinsky PF; Grubb RL; Falk RT; Hsing AW; Chu L; Meyer T; Veenstra TD; Xu X; Yu K; Ziegler RG; Brinton LA; Hoover RN; Cook MB
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2374-82. PubMed ID: 25178985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.
    Peskoe SB; Joshu CE; Rohrmann S; McGlynn KA; Nyante SJ; Bradwin G; Dobs AS; Kanarek N; Nelson WG; Platz EA
    Prostate; 2015 Aug; 75(11):1167-76. PubMed ID: 25919471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
    Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
    Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.
    Schenk JM; Till C; Hsing AW; Stanczyk FZ; Gong Z; Neuhouser ML; Reichardt JK; Hoque AM; Figg WD; Goodman PJ; Tangen CM; Thompson IM
    Cancer Causes Control; 2016 Feb; 27(2):175-82. PubMed ID: 26589415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPLC-RIA analysis of steroid hormone profile in a virilizing stromal tumor of the ovary.
    Szécsi M; Tóth I; Gardi J; Nyári T; Julesz J
    J Biochem Biophys Methods; 2004 Oct; 61(1-2):47-56. PubMed ID: 15560921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer risk: the significance of differences in age related changes in serum conjugated and unconjugated steroid hormone concentrations between Arab and Caucasian men.
    Kehinde EO; Akanji AO; Memon A; Bashir AA; Daar AS; Al-Awadi KA; Fatinikun T
    Int Urol Nephrol; 2006; 38(1):33-44. PubMed ID: 16502050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry.
    Dorgan JF; Fears TR; McMahon RP; Aronson Friedman L; Patterson BH; Greenhut SF
    Steroids; 2002 Mar; 67(3-4):151-8. PubMed ID: 11856538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3).
    Ahn J; Schumacher FR; Berndt SI; Pfeiffer R; Albanes D; Andriole GL; Ardanaz E; Boeing H; Bueno-de-Mesquita B; Chanock SJ; Clavel-Chapelon F; Diver WR; Feigelson HS; Gaziano JM; Giovannucci E; Haiman CA; Henderson BE; Hoover RN; Kolonel LN; Kraft P; Ma J; Le Marchand L; Overvad K; Palli D; Stattin P; Stampfer M; Stram DO; Thomas G; Thun MJ; Travis RC; Trichopoulos D; Virtamo J; Weinstein SJ; Yeager M; Kaaks R; Hunter DJ; Hayes RB
    Hum Mol Genet; 2009 Oct; 18(19):3749-57. PubMed ID: 19574343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age, body mass index, race and other determinants of steroid hormone variability: the HERITAGE Family Study.
    Ukkola O; Gagnon J; Rankinen T; Thompson PA; Hong Y; Leon AS; Rao DC; Skinner JS; Wilmore JH; Bouchard C
    Eur J Endocrinol; 2001 Jul; 145(1):1-9. PubMed ID: 11415846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.
    Belledant A; Hovington H; Garcia L; Caron P; Brisson H; Villeneuve L; Simonyan D; Têtu B; Fradet Y; Lacombe L; Guillemette C; Lévesque E
    Eur Urol; 2016 Apr; 69(4):601-609. PubMed ID: 26215610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
    Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women.
    Falk RT; Gentzschein E; Stanczyk FZ; Garcia-Closas M; Figueroa JD; Ioffe OB; Lissowska J; Brinton LA; Sherman ME
    Breast Cancer Res Treat; 2012 Jan; 131(1):287-94. PubMed ID: 21870130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    Tsilidis KK; Travis RC; Appleby PN; Allen NE; Lindstrom S; Schumacher FR; Cox D; Hsing AW; Ma J; Severi G; Albanes D; Virtamo J; Boeing H; Bueno-de-Mesquita HB; Johansson M; Quirós JR; Riboli E; Siddiq A; Tjønneland A; Trichopoulos D; Tumino R; Gaziano JM; Giovannucci E; Hunter DJ; Kraft P; Stampfer MJ; Giles GG; Andriole GL; Berndt SI; Chanock SJ; Hayes RB; Key TJ
    Am J Epidemiol; 2012 May; 175(9):926-35. PubMed ID: 22459122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediagnostic serum hormones and the risk of prostate cancer.
    Nomura A; Heilbrun LK; Stemmermann GN; Judd HL
    Cancer Res; 1988 Jun; 48(12):3515-7. PubMed ID: 3370644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.
    Sun T; Oh WK; Jacobus S; Regan M; Pomerantz M; Freedman ML; Lee GS; Kantoff PW
    Cancer Prev Res (Phila); 2011 Dec; 4(12):2044-50. PubMed ID: 21900597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies.
    Eaton NE; Reeves GK; Appleby PN; Key TJ
    Br J Cancer; 1999 Jun; 80(7):930-4. PubMed ID: 10362098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.